NEW YORK – GeneCentric Therapeutics said on Wednesday that it is entering a research collaboration with Janssen Research & Development around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).
Using GeneCentric's RNA-based molecular profiling platform, the partners will identify potential signatures of disease progression and drug response to standard-of-care therapy, including the role of genomic alterations in the fibroblast growth factor receptor (FGFR), which are among the more common tumor mutations in these patients.